A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Public ClinicalTrials.gov record NCT00606684. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study B2C111045, A Dose-Finding Study of GW642444 Versus Placebo in Patients With COPD
Study identification
- NCT ID
- NCT00606684
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 602 participants
Conditions and interventions
Conditions
Interventions
- GW642444 6.25 Drug
- GW642444 3mcg Drug
- GW642444 12.5mcg Drug
- GW642444 25mcg Drug
- GW642444 50mcg Drug
- placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2008
- Primary completion
- Sep 30, 2008
- Completion
- Sep 30, 2008
- Last update posted
- Dec 15, 2016
2008
United States locations
- U.S. sites
- 49
- U.S. states
- 20
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Florence | Alabama | 35630 | — |
| GSK Investigational Site | Jasper | Alabama | 35501 | — |
| GSK Investigational Site | Montgomery | Alabama | 36109 | — |
| GSK Investigational Site | Fullerton | California | 92835 | — |
| GSK Investigational Site | Lakewood | California | 90712 | — |
| GSK Investigational Site | Los Angeles | California | 90095-1752 | — |
| GSK Investigational Site | Rancho Mirage | California | 92270 | — |
| GSK Investigational Site | Sepuldeva | California | 91343 | — |
| GSK Investigational Site | Upland | California | 91786 | — |
| GSK Investigational Site | Newark | Delaware | 19713 | — |
| GSK Investigational Site | Brandon | Florida | 33511 | — |
| GSK Investigational Site | DeLand | Florida | 32720 | — |
| GSK Investigational Site | Miami | Florida | 33136 | — |
| GSK Investigational Site | Tampa | Florida | 33613 | — |
| GSK Investigational Site | Marietta | Georgia | 30060 | — |
| GSK Investigational Site | Carmel | Indiana | 46032 | — |
| GSK Investigational Site | Elkhart | Indiana | 46515 | — |
| GSK Investigational Site | New Albany | Indiana | 47150 | — |
| GSK Investigational Site | Lafayette | Louisiana | 70503 | — |
| GSK Investigational Site | Sunset | Louisiana | 70584 | — |
| GSK Investigational Site | Detroit | Michigan | 48201-2018 | — |
| GSK Investigational Site | Livonia | Michigan | 48152 | — |
| GSK Investigational Site | Saint Charles | Missouri | 63301 | — |
| GSK Investigational Site | St Louis | Missouri | 63122 | — |
| GSK Investigational Site | St Louis | Missouri | 63141 | — |
| GSK Investigational Site | Butte | Montana | 59701 | — |
| GSK Investigational Site | Summit | New Jersey | 07091 | — |
| GSK Investigational Site | Elmira | New York | 14901 | — |
| GSK Investigational Site | Larchmont | New York | 10538 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28207 | — |
| GSK Investigational Site | Greenville | North Carolina | 27834 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27607 | — |
| GSK Investigational Site | Statesville | North Carolina | 28625 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45231 | — |
| GSK Investigational Site | Medford | Oregon | 97504 | — |
| GSK Investigational Site | Portland | Oregon | 97220 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| GSK Investigational Site | Charleston | South Carolina | 29406-7108 | — |
| GSK Investigational Site | Gaffney | South Carolina | 29340 | — |
| GSK Investigational Site | Greenville | South Carolina | 29615 | — |
| GSK Investigational Site | Spartanburg | South Carolina | 29303 | — |
| GSK Investigational Site | Union | South Carolina | 29379 | — |
| GSK Investigational Site | Corsicana | Texas | 75110 | — |
| GSK Investigational Site | Dallas | Texas | 75216 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Waco | Texas | 76712 | — |
| GSK Investigational Site | South Burlington | Vermont | 05403 | — |
| GSK Investigational Site | Abingdon | Virginia | 24210 | — |
| GSK Investigational Site | Richmond | Virginia | 23225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00606684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 15, 2016 · Synced Jun 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00606684 live on ClinicalTrials.gov.